Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Glaukos Corporation Common Stock (NY:GKOS)

93.94 +3.80 (+4.22%)
Official Closing Price Updated: 7:00 PM EDT, Sep 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Glaukos Corporation Common Stock

< Previous 1 2 3 4 5 6 Next >
Glaukos (GKOS) Q2 Revenue Jumps 30%
Via The Motley Fool
Earnings Scheduled For July 30, 2025
 
Via Benzinga
What 11 Analyst Ratings Have To Say About Glaukos
 
Via Benzinga
This Parsons Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday
 
Via Benzinga
Earnings Scheduled For April 30, 2025
 
Via Benzinga
Forecasting The Future: 7 Analyst Projections For Glaukos
 
Via Benzinga
Here's How Much You Would Have Made Owning Glaukos Stock In The Last 5 Years
 
Via Benzinga
Here's How Much $100 Invested In Glaukos 5 Years Ago Would Be Worth Today
 
Via Benzinga
Earnings Scheduled For February 20, 2025
 
Via Benzinga
Peering Into Glaukos's Recent Short Interest
 
Via Benzinga
How Is The Market Feeling About Glaukos?
 
Via Benzinga
FDA Sets Decision Date For Glaukos' Keratoconus Treatment Without The Need Of Surgery
Glaukos' Epioxa NDA for keratoconus is under FDA review, with a decision expected by October 2025. Phase 3 trials support its non-invasive treatment potential. 
Via Benzinga
Consumer Sentiment Drops 10%, UnitedHealth Under Investigation: What's Driving Markets Friday?
All three major U.S. stock indices are down Friday as traders reacted to several sets of fresh data that raised concerns about the economic outlook.  
Via Benzinga
Glaukos Delivers Mixed Q4 Results, Analyst Sees Growing Investor Interest During Transition
Glaukos reported Q4 sales of $105.5 million, surpassing estimates, while EPS missed. Analysts see strong growth potential as the company expands its business model. 
Via Benzinga
Wondering what's happening in today's after-hours session?
As the regular session of the US market on Thursday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
Via Chartmill
$1000 Invested In Glaukos 5 Years Ago Would Be Worth This Much Today
 
Via Benzinga
What 11 Analyst Ratings Have To Say About Glaukos
 
Via Benzinga
This NetApp Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday
 
Via Benzinga
Short Seller Accuses TransMedics Of 'Mafia Style' Scheme, Organ Transplant Company Says Short Seller Manipulating Market
TransMedics faces allegations from Scorpion Capital of fraud and organ trafficking, while the company rebuffs the claims as baseless market manipulation. 
Via Benzinga
Topics Fraud
Glaukos To Rally Around 17%? Here Are 6 Top Analyst Forecasts For Tuesday
 
Via Benzinga
(GKOS) - Analyzing Glaukos's Short Interest
 
Via Benzinga
Wall Street's Top 10 Stock Calls This Week - Saturday, Dec. 7
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Dec. 2-6, 2024. 
Via Talk Markets
Topics Stocks / Equities
How Is The Market Feeling About Glaukos?
 
Via Benzinga
Analyst Scoreboard: 5 Ratings For Glaukos
 
Via Benzinga
How Is The Market Feeling About Glaukos?
 
Via Benzinga
A Closer Look at 7 Analyst Recommendations For Glaukos
 
Via Benzinga
This Constellation Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
 
Via Benzinga
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos
Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges. 
Via Benzinga
This Kohl's Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
 
Via Benzinga
Glaukos Reports 30% Boost In Glaucoma Sales, Improved Margins In Q3, Analyst Highlights Certain Headwinds
Glaukos Corporation's Q3 revenue grew 24% to $96.7 million, beating estimates, with an EPS loss of $(0.28). 2024 sales guidance raised despite anticipated headwinds. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.